A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia with Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Nelotanserin (Primary)
- Indications Dementia; Lewy body disease; Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Axovant Sciences
- 29 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
- 29 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
- 09 Jan 2017 According to an Axovant media release, results from the study are expected in the second half of 2017.